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The authors of the above-mentioned paper
noticed some errors subsequent to publication
and would like to make the following
corrections.
On pages 5 and 6, Table 1 will include a
footnote for the prior non-Omnitrope rhGH
therapy: ‘‘These patients are not mutually
exclusive, they could have been on multiple
GH therapies prior to switching to Omnitrope’’.
On page 10 under the heading Discussion
the recommended dose of GH therapy in TS
patients pre- and post-switch should be
0.33 mg/kg/week. The sentence should now
read ‘‘We recognize that the GH therapy dose
that was used in TS patients pre- and post-
switch was less than the recommended dose of
0.33 mg/kg/week’’.
Open Access. This article is distributed
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